An observational study in Non-Small Cell Lung Cancer, Malignant Neoplasm and Pulmonary Nodules, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.
Sponsored by Peking University People's Hospital · Observational
Lung malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. CDH3 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous epithelial cells. A new PET probe, 68Ga-TOI-1, targeting CDH3 has been developed with better affinity and selectivity than previous probes. Preclinical data support its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of lung tumors, providing a new and precise evaluation method for lung malignant tumors.
Cancer is a leading cause of high mortality rates worldwide and a significant barrier to increasing life expectancy. Among various cancer types, lung cancer is one of the most common malignant tumors globally. According to global cancer statistics, as of 2020, the global incidence rate of lung cancer was 11.4%, and the mortality rate was 18%. Lung cancer is a major cause of cancer-related deaths in China and worldwide, particularly non-small cell lung cancer (NSCLC), and its treatment strategies are continuously evolving. Immunotherapy and targeted neoadjuvant therapy can help eliminate micrometastases to reduce postoperative recurrence, lower tumor staging to improve the resectability of primary lesions, and enhance the long-term survival rate of lung cancer patients to some extent. However, for patients with resectable lung cancer, surgery remains the primary curative approach.
Given the significant individual variability in lung cancer treatment outcomes, the suboptimal efficacy of traditional PET in monitoring treatment response, and the lack of effective methods for distinguishing benign from malignant pulmonary nodules, there is a critical clinical need for innovative approaches. Leveraging key molecular imaging markers for preoperative assessment of treatment efficacy and assisting in the differentiation of benign and malignant pulmonary nodules is a crucial scientific direction for our research team.
In recent years, molecular imaging has been increasingly applied in cancer diagnosis and treatment, with PET molecular imaging emerging as a key tool for lung cancer management. By utilizing targeting moieties of molecular probes to precisely bind to tumor biomarkers, coupled with radiation emitted from radionuclides during decay, it is possible to achieve accurate lesion detection and non-invasive monitoring. This approach holds promise for overcoming longstanding challenges in conventional PET imaging for comprehensive lung cancer treatment, such as high false-positive rates.
High-dimensional multi-omics technologies integrate data from genomics, transcriptomics, proteomics, and other levels. By employing transcriptomics and proteomics, overexpressed proteins in lung cancer tissues can be identified at the tissue level, while spatial transcriptomics and single-cell transcriptomics can validate the cellular localization of target proteins. Multi-omics approaches enable systematic exploration of key molecular targets in lung cancer, providing a reliable pathway for precision target discovery. Utilizing a previously established large-scale Chinese multi-omics lung cancer cohort, combined with bioinformatics analysis and in vitro and in vivo molecular biology validation, the investigators identified CDH3 as a surface biomarker for non-small cell lung cancer.
Cadherin-3 (CDH3) is a glycoprotein whose abnormal high expression in non-small cell lung cancer is closely associated with poor prognosis, enhanced tumor proliferation and migration, and the formation of an immunosuppressive microenvironment. CDH3 has emerged as a promising novel therapeutic target for lung cancer. Currently, drug development targeting CDH3 primarily focuses on antibody-drug conjugates (ADCs). In a study involving five patients with advanced NSCLC harboring EGFR mutations, these drugs achieved an objective response rate as high as 80%. Through multi-omics imaging target screening, CDH3 was identified as a potential imaging target due to its specific high expression on the surface of lung cancer cells.
Supported by a key project from the National Natural Science Foundation of China, our team has previously developed a CDH3-targeted molecular probe, TOI-1, with independent intellectual property rights and has applied for a patent (published under publication number CN121426959A). This probe has demonstrated excellent sensitivity and specificity in preclinical animal models. the investigators are now collaborating with the Department of Nuclear Medicine at our hospital to conduct an exploratory clinical study on the 68Ga-TOI-1 PET molecular probe. 68Ga-TOI-1 PET/CT imaging is expected to help determine the benign or malignant nature of tumors and their extent of involvement, enable tumor localization and qualitative diagnosis, facilitate early diagnosis and restaging of recurrent tumors, and provide scientific evidence for disease staging, disease activity assessment, treatment planning, and prognosis evaluation.
7,620 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
This study's planned enrollment of 80 is below the median of 160 across 1,148 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Peking University People's Hospital is the lead sponsor of 609 studies on the registry; 247 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This single-center, prospective, single-arm study plans to enroll 30 patients with lung cancer receiving neoadjuvant immunochemotherapy and 50 patients with pulmonary nodules highly suspected of malignancy based on clinical diagnostic criteria who are scheduled to undergo wedge resection or anatomic lobectomy/sublobar resection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant who conforms to the inclusion criteria will undergo 18F-FDG and 68Ga-CDH3 PET/CT scans within 1 week.
Diagnostic Test: PET/CT scans
PET Dynamic Data: The tracer is administered based on the patient's body weight at approximately 0.06-0.12 mCi/kg. PET scanning is initiated simultaneously with tracer injection, followed by a flush with 10 ml of normal saline. The image acquisition matrix is 192 × 192. Reconstruction is performed using the OSEM algorithm with 4 iterations and 20 subsets, incorporating time-of-flight attenuation correction, scatter correction, and random correction. The total duration of PET dynamic data acquisition is 60 minutes. Processing of PET dynamic scan data: Dynamic PET images are divided into 2-minute intervals to obtain time-activity curves by extracting the radioactivity within regions of interest at different time points, reflecting tracer uptake and enabling calculation of the time to peak. Multi-modality imaging data are analyzed by radiologists with over 10 years of experience in diagnosing respiratory diseases.
The diagnostic sensitivity and specificity of 68Ga-TOI-1 PET/CT in the staging of lung malignant tumors.
The diagnostic performance of 68Ga-TOI-1 PET/CT and 18F-FDG PET/CT for initial staging will be evaluated and compared using histopathological findings or typical imaging features as reference standard.
Time frame: up to 6 weeks
Maximum Standardized Uptake Value [SUVmax] of Primary and Metastatic Lesions on 68Ga-TOI-1 PET/CT vs. 18F-FDG PET/CT
Comparison of maximum standardized uptake value (SUVmax) of primary and metastatic lesions between 68Ga-TOI-1 PET/CT and 18F-FDG PET/CT.
Time frame: up to 6 weeks
Mean Standardized Uptake Value [SUVmean] of Primary and Metastatic Lesions on 68Ga-TOI-1 PET/CT vs. 18F-FDG PET/CT
Comparison of mean standardized uptake value (SUVmean) of primary and metastatic lesions between 68Ga-TOI-1 PET/CT and 18F-FDG PET/CT.
Time frame: up to 6 weeks
Correlation between 68Ga-TOI-1 SUVmax and CDH3 H-score in Tumor Tissue
Evaluation of the correlation between maximum standardized uptake value (SUVmax) derived from 68Ga-TOI-1 PET/CT and CDH3 expression level measured by immunohistochemistry (IHC) as H-score (combining staining intensity and percentage of positive cells) in tumor tissue samples.
Time frame: up to 6 weeks
Correlation between 68Ga-TOI-1 SUVmean and CDH3 H-score in Tumor Tissue
Evaluation of the correlation between mean standardized uptake value (SUVmean) derived from 68Ga-TOI-1 PET/CT and CDH3 expression level measured by immunohistochemistry (IHC) as H-score (combining staining intensity and percentage of positive cells) in tumor tissue samples.
Time frame: up to 6 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Peking University People's Hospital →